{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:44:58Z","timestamp":1790876698001,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.oret.2025.12.014","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:03:58Z","timestamp":1766448238000},"page":"480-489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of Glucagon-Like Peptide-1 Receptor Agonists on Age-Related Macular Degeneration at a Tertiary Ophthalmology Center"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1299-8144","authenticated-orcid":false,"given":"Julia H.","family":"Joo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison H.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghana","family":"Chalasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Allan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra V.","family":"Rachitskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2025.12.014_bib1","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.oret.2025.12.014_bib2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.neuron.2012.06.018","article-title":"Mechanisms of age-related macular degeneration","volume":"75","author":"Ambati","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.oret.2025.12.014_bib3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2023.26074","article-title":"Age-related macular degeneration: a review","volume":"331","author":"Fleckenstein","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.oret.2025.12.014_bib4","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/S0161-6420(00)00409-7","article-title":"Risk factors associated with age-related macular degeneration: a case-control study in the age-related eye disease study: age-related eye disease study report number 3","volume":"107","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.12.014_bib5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1350-9462(00)00023-9","article-title":"Risk factors for age-related macular degeneration","volume":"20","author":"Evans","year":"2001","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.oret.2025.12.014_bib6","first-page":"16","article-title":"Modifiable lifestyle risk factors and strategies for slowing the progression of age-related macular degeneration","volume":"9","author":"Saigal","year":"2025","journal-title":"Vis Basel Switz"},{"key":"10.1016\/j.oret.2025.12.014_bib7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ophtha.2008.09.019","article-title":"Risk of advanced age-related macular degeneration following cataract surgery in the Age-Related Eye Disease Study","volume":"116","author":"Chew","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.12.014_bib8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/APO.0000000000000496","article-title":"Age-related macular degeneration and cardiovascular diseases: revisiting the common soil theory","volume":"11","author":"Mauschitz","year":"2022","journal-title":"Asia-Pac J Ophthalmol"},{"key":"10.1016\/j.oret.2025.12.014_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101442","article-title":"Association between glycemic status and age-related macular degeneration: a nationwide population-based cohort study","volume":"49","author":"Lee","year":"2023","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.oret.2025.12.014_bib10","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.2337\/dc18-0707","article-title":"The association between diabetes and age-related macular degeneration among the elderly in Taiwan","volume":"41","author":"He","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.oret.2025.12.014_bib11","article-title":"Diabetes mellitus and risk of age-related macular degeneration: a systematic review and meta-analysis","volume":"9","author":"Chen","year":"2014","journal-title":"PLOS One"},{"key":"10.1016\/j.oret.2025.12.014_bib12","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1167\/iovs.18-26422","article-title":"The common antidiabetic drug metformin reduces odds of developing age-related macular degeneration","volume":"60","author":"Brown","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2025.12.014_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083759","article-title":"Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration","volume":"8","author":"Guymer","year":"2013","journal-title":"PLOS One"},{"key":"10.1016\/j.oret.2025.12.014_bib14","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.oret.2025.12.014_bib15","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.amjmed.2025.01.021","article-title":"Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation","volume":"138","author":"Moiz","year":"2025","journal-title":"Am J Med"},{"key":"10.1016\/j.oret.2025.12.014_bib16","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oret.2025.12.014_bib17","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.oret.2025.12.014_bib18","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.oret.2025.12.014_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012428","article-title":"Anti-inflammatory effects of GLP-1R activation in the retina","volume":"23","author":"Puddu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.oret.2025.12.014_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108271","article-title":"GLP-1 receptor agonist NLY01 reduces retinal inflammation and neuron death secondary to ocular hypertension","volume":"33","author":"Sterling","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.oret.2025.12.014_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.oret.2025.12.014_bib22","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/db15-0443","article-title":"Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes","volume":"65","author":"Hern\u00e1ndez","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.oret.2025.12.014_bib23","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ophtha.2024.03.004","article-title":"Association between glucagon-like peptide-1 receptor agonists and the risk of glaucoma in individuals with type 2 diabetes","volume":"131","author":"Niazi","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.12.014_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2024.100547","article-title":"The effect of glucagon-like peptide-1 receptor agonists on diabetic retinopathy at a tertiary care center","volume":"4","author":"Joo","year":"2024","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.oret.2025.12.014_bib25","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ophtha.2025.01.016","article-title":"Glucagon-like peptide-1 receptor agonist impact on chronic ocular disease including age-related macular degeneration","volume":"132","author":"Allan","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.12.014_bib26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ajo.2025.02.025","article-title":"The effect of semaglutide and GLP-1 RAs on risk of nonarteritic anterior ischemic optic neuropathy","volume":"274","author":"Abbass","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2025.12.014_bib27","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.ophtha.2025.02.011","article-title":"Risk of glaucoma in non-diabetic patients using a glucagon like peptide-1 receptor agonist","volume":"132","author":"Vasu","year":"2025","journal-title":"Ophthalmology"},{"issue":"0","key":"10.1016\/j.oret.2025.12.014_bib55","article-title":"Glucagon-like peptide-1 receptor agonists: What ophthalmologists need to know","volume":"0","author":"Bala","year":"2025","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.oret.2025.12.014_bib28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/jamaophthalmol.2025.1455","article-title":"Glucagon-like peptide-1 receptor agonists and risk of neovascular age-related macular degeneration","volume":"143","author":"Shor","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2025.12.014_bib29","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ajo.2024.08.037","article-title":"Comment on impact of GLP-1 agonists and SGLT-2 inhibitors on diabetic retinopathy progression: an aggregated electronic health record study","volume":"268","author":"Lum","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2025.12.014_bib30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1001\/jamaophthalmol.2023.5478","article-title":"Metformin use and age-related macular degeneration in patients without diabetes","volume":"142","author":"Aggarwal","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2025.12.014_bib31","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/jamaophthalmol.2020.6331","article-title":"Association of metformin use with age-related macular degeneration: a case-control study","volume":"139","author":"Blitzer","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2025.12.014_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1008922","article-title":"Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: data from basic science and clinical trials","volume":"9","author":"Scisciola","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.oret.2025.12.014_bib33","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.oret.2022.11.012","article-title":"The underreporting of age-related geographic atrophy of the macula see editorial on page 287","volume":"7","author":"Sunness","year":"2023","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.12.014_bib34","article-title":"Forester: an R package for creating #> publication-ready forest plots","author":"Boyes","year":"2021","journal-title":"R package version 0.3.0"},{"key":"10.1016\/j.oret.2025.12.014_bib35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40035-024-00431-y","article-title":"SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system","volume":"13","author":"Mei","year":"2024","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.oret.2025.12.014_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-021-00265-2","article-title":"Age-related macular degeneration","volume":"7","author":"Fleckenstein","year":"2021","journal-title":"Nat Rev Dis Primer"},{"key":"10.1016\/j.oret.2025.12.014_bib37","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1097\/IAE.0000000000004616","article-title":"Impact of GLP-1 receptor agonists for type 2 diabetes mellitus on the development and progression of age-related macular degeneration","volume":"45","author":"McLaughlin","year":"2025","journal-title":"Retina"},{"key":"10.1016\/j.oret.2025.12.014_bib38","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/jamaophthalmol.2025.3821","article-title":"Glucagon-like peptide-1 receptor agonists and age-related macular degeneration","volume":"143","author":"Ahuja","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"25","key":"10.1016\/j.oret.2025.12.014_bib39","first-page":"S2468","article-title":"Glucagon-like peptide-1 receptor agonist use and risk of neovascular age-related macular degeneration in a National Cohort Study","author":"Allan","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.12.014_bib40","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oret.2025.12.014_bib41","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oret.2025.12.014_bib42","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oret.2025.12.014_bib43","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2165\/11635890-000000000-00000","article-title":"Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection","volume":"26","author":"H\u00f6lscher","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.oret.2025.12.014_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.oret.2025.12.014_bib45","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","article-title":"The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson\u2019s disease: mechanisms of action","volume":"21","author":"Athauda","year":"2016","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.oret.2025.12.014_bib46","doi-asserted-by":"crossref","first-page":"9583","DOI":"10.3390\/ijms23179583","article-title":"Anti-Inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases","volume":"23","author":"Diz-Chaves","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.oret.2025.12.014_bib47","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1080\/02699052.2019.1587000","article-title":"GLP-1\u2019s role in neuroprotection: a systematic review","volume":"33","author":"Erbil","year":"2019","journal-title":"Brain Inj"},{"key":"10.1016\/j.oret.2025.12.014_bib48","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/ICU.0000000000001137","article-title":"Glucagon-like peptide-1 receptor agonists and the eye","volume":"36","author":"Zhang","year":"2025","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.oret.2025.12.014_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2023.1156829","article-title":"Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma","volume":"17","author":"Lawrence","year":"2023","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.oret.2025.12.014_bib50","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/bjophthalmol-2021-319232","article-title":"Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma","volume":"107","author":"Sterling","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2025.12.014_bib51","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/bjo.2007.131581","article-title":"Inflammation in the pathogenesis of age-related macular degeneration","volume":"92","author":"Kanda","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2025.12.014_bib52","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/opo.12671","article-title":"Contribution of microglia and monocytes to the development and progression of age related macular degeneration","volume":"40","author":"Fletcher","year":"2020","journal-title":"Ophthalmic Physiol Opt"},{"key":"10.1016\/j.oret.2025.12.014_bib53","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jamaophthalmol.2025.0350","article-title":"Conflicting results\u2014need for more transparent and reproducible research","volume":"143","author":"Cai","year":"2025","journal-title":"JAMA Ophthalmol"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025005950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025005950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:28:13Z","timestamp":1777602493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653025005950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2468653025005950"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2025.12.014","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Glucagon-Like Peptide-1 Receptor Agonists on Age-Related Macular Degeneration at a Tertiary Ophthalmology Center","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2025.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}